Targeting the trimolecular complex.

Abstract

Class II major histocompatibility molecules (MHC) confer disease risk for multiple autoimmune disorders including type 1 diabetes. The interaction between the components of the trimolecular complex (CD4(+) T cell receptors, self-peptide, and MHC class II molecules) plays a pivotal role in autoimmune disease pathogenesis. The development of therapies targeting various components of the trimolecular complex for the prevention of type 1 diabetes is actively being pursued. This review focuses on the components of the anti-insulin trimolecular complex, registers of insulin peptide binding to 'diabetogenic' MHC class II molecules, and therapies targeting each component of the trimolecular complex.

• Authors: Aaron W Michels
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 149 Issue 3 Pg. 339-44 (Dec 2013) ISSN: 1521-7035 [Electronic] United States
• PMID: 23537861 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2013 Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Autoantigens
• Histocompatibility Antigens Class II
• Hypoglycemic Agents
• Insulin
• Peptides
• Receptors, Antigen, T-Cell

Topics

• Amino Acid Motifs
• Antibodies, Monoclonal (therapeutic use)
• Autoantigens (immunology, metabolism)
• CD4-Positive T-Lymphocytes (drug effects, immunology, pathology)
• Diabetes Mellitus, Type 1 (drug therapy, immunology, pathology)
• Histocompatibility Antigens Class II (immunology, metabolism)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin (immunology, metabolism)
• Molecular Sequence Data
• Peptides (immunology, metabolism)
• Receptors, Antigen, T-Cell (immunology, metabolism)